While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...
The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.
Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven ...
Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.